Personalizing Treatment of Early-Stage Breast Cancer
Emiel J. Rutgers, MD, from the Netherlands Cancer Institute, describes the personalization of treatment for patients with early-stage breast cancer.
Emiel J. Rutgers, MD, surgical oncologist, Netherlands Cancer Institute, Amsterdam, describes the personalization of treatment for patients with early-stage breast cancer.
Clinical Pearls
In this group of patients, a physician must look at the results of a sentinel node biopsy and consider the primary tumor characteristics. If there is low tumor involvement, a physician would most likely determine that no treatment of the axial is adequate. If a patient has more tumor involvement in the sentinel nodes and larger tumor burden in the breast, elective treatment of the axilla with radiotherapy is a good strategy.
- In patients with low tumor involvement, no treatment of the axilla is adequate
- In patients with more tumor involvement in the sentinel nodes, elective treatment of the axilla with radiotherapy is a good strategy
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Rugo Surveys Peers on Treatment After Metastatic Relapse of HR+, HER2– Breast Cancer
April 20th 2024During a Case-Based Roundtable® event, Hope S. Rugo, MD, FASCO, moderated a discussion on treatment options for a patient whose breast cancer recurred several years after adjuvant therapy.
Read More
